We aim to help advance cancer immunotherapies and targeted therapies by applying cutting-edge genomic and informatics technologies to solve important problems in cancer biology. Our laboratory combines computational (dry) and experimental (wet) approaches to uncover both systematic trends and specific elements influencing oncogenic processes, tumor microenvironment, and drug responses. First, we use single cell sequencing technologies to delineate the detailed composition and functional status of the tumor microenvironment, in particular the landscape of the tumor infiltrating lymphocytes. We also use single cell technologies to address tumor heterogeneity and how such heterogeneity influence cancer cell evolution and drug responses. Second, we apply advanced bioinformatics methods to the ever expanding cancer genomics “big data” to reveal cancer subtypes, driver genes, and underlying genetics basis leading to functional events such as gene fusions, allele-specific expression, and tumor-specific expression isoforms. Third, we develop innovative bioinformatics tools to analyze, integrate and visualize single cell genomics data as well as large-scale cancer genomics data so that such data can effectively serve the wide research community.
Dr. Zhang obtained his Bachler degree in Genetics from Nankai University, and PhD in Biochemistry and Molecular Biology from Penn State University. He received additional training in Information Technology from UC Berkeley and postdoctoral trainings in Laboratory Medicine from UC San Francisco.
Prior to joining Peking University, Dr. Zhang spent over 16 years at Genentech/Roche, leading the cancer genomics and bioinformatics group to discover anticancer targets and biomarkers using new technologies such as machine learning and high throughput sequencing. He has pioneered multiple research directions in computational cancer biology and cancer genomics including the first ever whole genome tumor sequencing. He is also an inventor for 60 issued US patents, and has directly contributed to the initial finding of the molecular targets of multiple cancer therapeutic agents in clinical trials. He is on the editorial boards for journals including Cell Systems, Genome Medicine, and Cancer Informatics. He is a CUSBEA Scholar, a recipient of the 1000 Talents program, and also a Cheung Kong Scholar.
在加入北京大学之前，张博士在著名生物医药公司基因泰克/罗氏（Genentech/Roche）工作了16年，担任癌症基因组学和生物信息学组的首席，致力于应用机器学习和高通量测序等高新技术进行抗癌药靶和生物标记物的发现。他在计算癌症生物学和癌症基因组学的多个方向上都是开拓者、引领者，如世界首例肿瘤全基因组测序即由张博士领导完成。张博士同时也是60个已获得授权的美国专利的发明人，并在目前正在临床试验中的多项癌症治疗药物的分子靶标的原创发现中做出了直接贡献。他同时也是多家国际知名杂志如Cell Systems、Genome Medicine和Cancer Informatics的编委。他先后获得了CUSBEA学者、中组部千人计划学者和教育部长江特聘教授等荣誉。
Posted on June 16, 2017
Systematic interrogation of tumor-infiltrating lymphocytes is key to the development of immunotherapies and the prediction of their clinical responses in cancers. We performed deep single-cell RNA sequencing on 5,063 single T cells isolated from peripheral blood, tumor, and adjacent normal tissues from six hepatocellular carcinoma patients. The transcriptional profiles ...